Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria-Reference-Cited by-同舟云学术

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

Published:2023-03 Issue:3 Volume:8 Page:499-506
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Lv Jicheng,Liu Lijun,Hao Chuanming,Li Guisen^ORCID,Fu Ping,Xing Guangqun,Zheng Hongguang,Chen Nan,Wang Caili,Luo Ping,Xie Deqiong,Zuo Li,Li Rongshan,Mao Yonghui,Dong Shaoshao,Zhang Pengfei,Zheng Huixiao,Wang Yue,Qin Wei^ORCID,Wang Wenxiang,Li Lin,Jiao Wenjuan,Fang Jianmin,Zhang Hong

Publisher

Elsevier BV

Subject

Nephrology

Reference32 articles.

1. KDIGO 2021 clinical practice guideline for the management of glomerular diseases;Rovin;Kidney Int,2021

2. IgA nephropathy: a brief review;Hassler;Semin Diagn Pathol,2020

3. IgA nephropathy: core curriculum 2021;Pattrapornpisut;Am J Kidney Dis,2021

4. Primary glomerulonephritides;Floege;Lancet (Lond Engl),2016

5. The pathophysiology of IgA nephropathy;Suzuki;J Am Soc Nephrol,2011

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination treatment with telitacicept, mycophenolate mofetil and glucocorticoids for immunoglobulin A nephropathy: A case report;World Journal of Clinical Cases;2024-10-16

2. Editorial: IgA nephropathy: a nephrologist’s challenge in 2023;Frontiers in Nephrology;2024-09-11

3. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases;Journal of Autoimmunity;2024-09

4. Targeting APRIL in the treatment of glomerular diseases;Kidney International;2024-09

5. Long-term renal survival in patients with IgA nephropathy: a systematic review;Renal Failure;2024-08-27